The bashers and complainers are out in full force on iHub today. Always interesting when they show up and start to respond to each other’s posts about how bad things are.
The science is great and promising, but funding is an issue. Leronlimab will be on the market in 2020 and making revenues, but at what cost to shareholders is the looming question.